Photo of Bexis

Last July we published a “Here’s Hoping” post that maybe the terrible decision in Atchley v. AstraZeneca UK Ltd., 22 F.4th 204 (D.C. Cir. 2022), allowing drug companies to be sued for purportedly “aiding and abetting” international terrorists (see our takedown of Atchley here), would fall in light of the Supreme Court’s

Photo of Michelle Yeary

Plaintiffs in mass tort drug and device litigation do not like to focus on the individual cases.  They like to amass the individual cases.  They like to file the individual cases.  But as we see all too often those filings tend to be indiscriminate and without the benefit of proper early vetting.  That is what

Photo of Michelle Yeary

On February 6, Dechert is proud to host the 2024 Life Sciences Day, an interdisciplinary program designed for in-house counsel, chief officers, and strategic investors. This dynamic half-day event will feature expert panels discussing key issues in the life sciences sector and include speakers from leading pharmaceutical and biotech companies.  

Our panelists will